{"title":"私人医疗保健机构rjd -医学组织，在新冠状病毒传播期间，COVID-19","authors":"М В Мелкумова","doi":"10.35177/2226-2342-2021-2-2","DOIUrl":null,"url":null,"abstract":"Actovegin use in patients with cognitive impairment after infection Objective: to investigate the effectiveness of long-term oral administration of Actovegin in post-COVID patients with cognitive impairment (CI). Patients and methods. 444 patients (142 men, 302 women) with COVID-19 and CI participated in the study. One-half of the included partici-pants – 222 patients (70 men and 152 women) – were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy; 222 patients (72 men and 150 women) were randomized to the control group. Cognitive functions were assessed with Montreal Cognitive Assessment (Montreal Cognitive Assessment test, МоСA test), fatigue – with Multidimensional Fatigue Inventory (MFI-20), emotional distur-bances – with Spielberger-Hanin test. Results and discussion. Post-COVID patients with CI in the Actovegin group after 60 days follow-up had higher mean MoCА scores (p<0.05), lower MFI (p<0.05), and Spielberger-Hanin test scores (p<0.05) compared to the control group. Conclusion. Positive effect of Actovegin on the cognitive functions and emotional state of post-COVID patients with CI was observed.","PeriodicalId":305067,"journal":{"name":"Vestnik obŝestvennogo zdorovʹâ i zdravoohraneniâ Dalʹnego Vostoka Rossii","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Организация работы частных учреждений здравоохранения \\\"РЖД-Медицина\\\" Дальневосточной железной дороги в период распространения новой коронавирусной инфекции COVID-19\",\"authors\":\"М В Мелкумова\",\"doi\":\"10.35177/2226-2342-2021-2-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Actovegin use in patients with cognitive impairment after infection Objective: to investigate the effectiveness of long-term oral administration of Actovegin in post-COVID patients with cognitive impairment (CI). Patients and methods. 444 patients (142 men, 302 women) with COVID-19 and CI participated in the study. One-half of the included partici-pants – 222 patients (70 men and 152 women) – were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy; 222 patients (72 men and 150 women) were randomized to the control group. Cognitive functions were assessed with Montreal Cognitive Assessment (Montreal Cognitive Assessment test, МоСA test), fatigue – with Multidimensional Fatigue Inventory (MFI-20), emotional distur-bances – with Spielberger-Hanin test. Results and discussion. Post-COVID patients with CI in the Actovegin group after 60 days follow-up had higher mean MoCА scores (p<0.05), lower MFI (p<0.05), and Spielberger-Hanin test scores (p<0.05) compared to the control group. Conclusion. Positive effect of Actovegin on the cognitive functions and emotional state of post-COVID patients with CI was observed.\",\"PeriodicalId\":305067,\"journal\":{\"name\":\"Vestnik obŝestvennogo zdorovʹâ i zdravoohraneniâ Dalʹnego Vostoka Rossii\",\"volume\":\"65 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vestnik obŝestvennogo zdorovʹâ i zdravoohraneniâ Dalʹnego Vostoka Rossii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35177/2226-2342-2021-2-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik obŝestvennogo zdorovʹâ i zdravoohraneniâ Dalʹnego Vostoka Rossii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35177/2226-2342-2021-2-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Организация работы частных учреждений здравоохранения "РЖД-Медицина" Дальневосточной железной дороги в период распространения новой коронавирусной инфекции COVID-19
Actovegin use in patients with cognitive impairment after infection Objective: to investigate the effectiveness of long-term oral administration of Actovegin in post-COVID patients with cognitive impairment (CI). Patients and methods. 444 patients (142 men, 302 women) with COVID-19 and CI participated in the study. One-half of the included partici-pants – 222 patients (70 men and 152 women) – were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy; 222 patients (72 men and 150 women) were randomized to the control group. Cognitive functions were assessed with Montreal Cognitive Assessment (Montreal Cognitive Assessment test, МоСA test), fatigue – with Multidimensional Fatigue Inventory (MFI-20), emotional distur-bances – with Spielberger-Hanin test. Results and discussion. Post-COVID patients with CI in the Actovegin group after 60 days follow-up had higher mean MoCА scores (p<0.05), lower MFI (p<0.05), and Spielberger-Hanin test scores (p<0.05) compared to the control group. Conclusion. Positive effect of Actovegin on the cognitive functions and emotional state of post-COVID patients with CI was observed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
